ClinicalTrials.gg
RecruitingNCT07038265BREAKUpdated Jun 26, 2025

Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)

An interventional study of Personalised treatment and Usual Care in Acute Coronary Syndromes (ACS), Cardiac Rehabilitation and Frailty, sponsored by Institut d'Investigació Biomèdica de Bellvitge. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Institut d'Investigació Biomèdica de Bellvitge · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.

Planned enrollment
42nd of 60
202 · median 588
Started
2025
with 5 others
No phase
24 of 85
4 open now
Primary completion
2027-11
later than 10 of 15 live
Registered
76th of 85
by date

Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 42nd largest by planned enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2025, is one of 24 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 76th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Acute Coronary Syndrome with a site in Spain, or all of them as a file.
02

Study summary

The primary objective of this study is to compare an integrated, multidisciplinar patient-centered CRP (Cardiac Rehabilitation Program) (intervention group) especially focused on covering the needs for the female and fragile population to the usual care conventional CRP (control group)

Read the detailed description

The Break-CR study is designed as an unicentric, open, randomized controlled trial, blind end-point evaluation and adjudication, to compare the feasibility, efficacy, and safety of a patient-centered CR-program versus usual care in patients after an acute coronary syndrome (ACS). The project aims to identify these barriers and design a CR-intervention to overcome said barriers and evaluate its usefulness in clinical practice.

The first part of this study consists of a qualitative study to specifically determine barriers, difficulties and facilitators that condition the participation of women in the CRPs, the second part of the study is undertaken to address the underrepresentation of women in CRPs and provide a solution to the recognized need to redesign CR programs to respond to the unique physiological and psychosocial needs of women. The aim is to design a groundbreaking intervention model that will respond to this need because it will incorporate all the factors on which a CR programme should be based, from a woman's perspective, from the beginning to the end, while also adressing the needs of the fragile portion ACS survivors.

It is hypothesized that the Break-CR program would be able to demonstrate greater improvements in incorporation and adherence of women and fragile patients to CR-programs, enhanced functional benefits, as well as improve patient-satisfaction and quality of life. Finally, the fundamental purpose is to enhance poor health outcomes of women and fragile patients with coronary diseases and to provide a solution that will contribute to bridge the health gap that exists in the field of cardiovascular diseases in health systems.

03

Conditions studied

  • Acute Coronary Syndromes (ACS)
  • Cardiac Rehabilitation
  • Frailty
  • Women
  • Women's Health

Keywords

  • frailty
  • sarcopenia
  • cardiac rehabilitation
  • gender perspective
  • acute coronary syndrome
  • coronary artery disease
  • patient-centered care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged ≥ 18 years
  2. Patients discharged within the last 30 days after an admission for ACS or in the discharge planning process for an admission for ACS.
  3. The patient is able to fully communicate with the research team and comply with all study procedures.
  4. The patient voluntarily signs and dates the form approved by the ethics committee

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years
  2. Participation in another clinical trial
  3. Moderate or severe cognitive impairment in the absence of a competent caregiver
  4. Absence of social support
  5. Institutionalized patient
  6. \<1 year
  7. Candidates for end-of-life care
  8. Severe psychiatric illness
  9. Planned cardiac surgery including transplant or circulatory support implant
  10. Death before hospital discharge in patients included in the hospital discharge planning phase
  11. Carrier of heart transplant.
  12. Patient unable or refusing to give written to participate
  13. Patients who, in the opinion of the investigator, are unsuitable candidates for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
202 participants (estimated)

Study arms

  • Active comparator
    Standard of care

    Usual cardiac rehabilitation program

    Other: Usual Care

  • Experimental
    Personalized intervention program

    BREAK intervention group with more alternatives of aerobic and strength exercises and also offering remote options for fragile patients

    Behavioral: Personalised treatment

Interventions

  • BehavioralPersonalised treatment

    Patients going through a personalized intervention program

  • OtherUsual Care

    Usual cardiac rehabilitation program

06

What researchers measure

Primary outcomes

  1. Improvement in functional capacity

    The primary endpoint of the study will be a composite functional capacity score, designed to capture the overall improvement in cardiorespiratory fitness following the rehabilitation intervention. This composite score will integrate the standardized change (from baseline to the end of the intervention) in the following four variables: 1. Peak oxygen uptake (VO₂ peak, in ml/kg/min), measured via cardiopulmonary exercise testing (CPET). 2. Six-minute walk distance (6MWD, in meters), assessed using the six-minute walk test. 3. Maximal metabolic equivalents (METs), achieved during CPET. 4. Exercise test duration (in minutes), defined as the total time sustained during the treadmill or cycle ergometer test under a standardized, symptom-limited protocol. Each of these variables will be converted to z-scores based on the distribution of change scores in the study population. The composite score will be calculated as the mean of the four standardized values

    Time frame: First visit and 3 months after hospital discharge (after completing rehabilitation program)

Secondary outcomes

  1. Physical Activity. IPAQ

    Adherence to physical activity will be evaluated with the International Physical Activity Questionnaire (IPAQ). The IPAQ classifies individuals into three categories of physical activity level based on intensity, frequency, and total energy expenditure (measured in MET·minutes/week): Category 1: Low Physical Activity: The person does not meet the criteria for moderate or high physical activity. Considered sedentary or insufficiently active. Category 2: Moderate Physical Activity. A person meets any of the following: * 3 days/week of vigorous activity ≥20 minutes/day, or * 5 days/week of moderate activity and/or walking ≥30 minutes/day, or * 5 days/week of any combination of walking, moderate, or vigorous activity totaling ≥600 MET·minutes/week. Category 3: High Physical Activity. A person meets either: * 3 days/week of vigorous activity accumulating ≥1,500 MET·minutes/week, or * 7 days/week of any combination of walking, moderate or vigorous activity totaling ≥3,000 MET·minutes/week

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge

  2. Physical Activity. Podometer

    According to pedometer readings which will be given to patients (steps/day), physical activity is categorized as follows: Sedentary or inactive \< 5,000 steps/day Low active 5,000-9,999 steps/day Active 10,000-12,499 steps/day Very active ≥ 12,500 steps/day

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital dischargeFirst visit and 6 months after hospital discharge

  3. Psychological status

    Psychological status will be evaluated for screening of anxiety and depression (PHQ-9 and GAD-7 scales). The PHQ-9 is a 9-item questionnaire used to screen for depression. Each item is scored from 0 (not at all) to 3 (nearly every day), with a total score range of 0-27. Cut-off points: 5-9: mild depression 10-14: moderate depression 15-19: moderately severe depression 20-27: severe depression The GAD-7 is a 7-item scale assessing generalized anxiety. Each item is scored 0-3 (same as PHQ-9), total score range: 0-21. Cut-off points: 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety A score ≥10 on either scale suggests clinically relevant symptoms, warranting further evaluation.

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital dischargeFirst Visit and 6 months after hospital discharge

  4. Dietary Changes

    ChatGPT Plus To assess dietary changes, we will use two validated tools: the DEBQ (Dutch Eating Behavior Questionnaire) and the PREDIMED Mediterranean Diet questionnaire. The DEBQ evaluates emotional, external, and restrained eating behaviors using 33 items rated on a 5-point scale (from "never" to "very often"). It helps identify if a patient eats more in response to emotions, sensory cues, or dieting efforts. Higher scores in each subscale indicate a stronger influence of that behavior on eating patterns. The PREDIMED questionnaire has 14 questions and measures adherence to the Mediterranean diet. Each healthy habit (e.g., using olive oil, eating fruits/vegetables, low processed food intake) scores 1 point. Scores ≥9 = good adherence, \<9 = low adherence. These tools allow monitoring of diet quality and behavior-related eating changes

    Time frame: In-hospital evaluation and 6 months after hospital discharge

  5. Body composition

    Nutritional status will be evaluated with the use of bioimpedanciometry (BIA), monitoring changes in body composition such as % of muscle and fat mass.

    Time frame: First visit and 3 months after hospital discharge (after completing rehabilitation program)

  6. Sarcopenia

    Sarcopenia will be assessed in patients using handgrip dynamometry, expressed in kilograms (kg). Handgrip strength (HGS) is a validated proxy for overall muscle strength and is widely used in clinical settings for sarcopenia screening. According to the international norms published by Tomkinson et al. (2025), cut-off values will be based on sex- and age-specific percentiles. Patients with HGS values below the 20th percentile for their age and sex will be considered at risk of sarcopenia. This threshold aligns with evidence suggesting that the lowest quintile is predictive of poorer health outcomes and increased mortality. These percentiles provide a robust, standardized reference to guide early intervention.

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge

  7. Frailty

    Frailty will be assessed using the Short Physical Performance Battery (SPPB), a validated tool that evaluates lower extremity function through three components: Balance (side-by-side, semi-tandem, tandem stand) Gait speed (usual pace over 4 meters) Chair stands (time to rise from a chair five times) Each component is scored from 0 to 4, giving a total score range of 0 to 12 (higher scores = better function). Cut-off points for frailty classification: 0-6 points: frail 7-9 points: pre-frail 10-12 points: robust This tool helps identify patients at risk of mobility disability and adverse outcomes and is recommended for use in both research and clinical practice.

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge

  8. Patient reported quality of life

    Changes in quality of life will be assessed using two validated instruments: the EuroQol-5D (EQ-5D) and the HeartQoL (HRQoL) questionnaire. (EQ-5D) This tool evaluates health across 5 dimensions: Mobility Self-care Usual activities Pain/discomfort Anxiety/depression Each dimension has 3 levels: no problems, some problems, and extreme problems. It also includes a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health), allowing patients to rate their overall health state. Higher scores indicate better perceived health. HRQoL The HRQoL is a disease-specific questionnaire for patients with ischemic heart disease. It has 14 items divided into two dimensions: Physical (10 items) Emotional (4 items) Each item is scored from 0 (worst HRQoL) to 3 (best HRQoL). Scores are averaged for each subscale and the global score; higher scores reflect better quality of life. Changes over time can reflect improvements or deterioration in health perception

    Time frame: First visit and 3 months after hospital discharge (after completing rehabilitation program)

  9. Sleep quality

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a standardized questionnaire that evaluates sleep patterns over the past month. The PSQI consists of 19 self-rated items grouped into 7 components: Subjective sleep quality Sleep latency Sleep duration Habitual sleep efficiency Sleep disturbances Use of sleeping medication Daytime dysfunction Each component is scored from 0 to 3, producing a global score ranging from 0 to 21. Scores ≤5: good sleep quality Scores \>5: poor sleep quality Higher scores reflect worse sleep quality. The PSQI is widely used in both research and clinical practice to monitor sleep-related changes and identify individuals with potential sleep disorders.

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge

  10. Sexual dysfunction

    Sexual dysfunction will be assessed using validated, sex-specific questionnaires: For men: IIEF (International Index of Erectile Function) The IIEF evaluates male sexual function over the past 4 weeks using 15 items distributed across 5 domains: Erectile function (items 1-5, 15) Orgasmic function (items 9-10) Sexual desire (items 11-12) Intercourse satisfaction (items 6-8) Overall satisfaction (items 13-14) Each item is scored from 0 or 1 to 5, with higher scores indicating better sexual function. Erectile dysfunction is usually classified as: 1-10: severe 11-16: moderate 17-25: mild to moderate 26-30: normal For women: FSM (Female Sexual Function Questionnaire) This tool consists of 19 items grouped into 6 domains: Desire (items 1-2) Arousal (items 3-6) Lubrication (items 7-10) Orgasm (items 11-13) Satisfaction (items 14-16) Pain (items 17-19) Some items are reverse-scored (8, 10, 12, 17-19). Higher total and subscale scores indicate better sexual function.

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge

  11. Readmission and mortality rates

    Readmission Rate (All-Cause and Cardiovascular) Patient outcomes will include evaluation of hospital readmissions, classified as: All-cause readmissions: any reason for hospital admission after discharge. Cardiovascular readmissions: admissions due to heart-related conditions (e.g., heart failure, myocardial infarction, arrhythmia). We will register both the rate (percentage of patients readmitted) and the total number of readmissions. A lower readmission rate reflects better clinical stability and care continuity. Mortality (All-Cause and Cardiovascular) Mortality will be monitored and classified into: All-cause mortality: death from any origin. Cardiovascular mortality: death due to cardiac or vascular causes (e.g., sudden cardiac death, stroke, heart failure). These indicators will evaluate patient prognosis and treatment effectiveness over the follow-up period.

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge

  12. Adherence to program

    Patient adherence and retention will be evaluated as follows: 1.1 Adherence analysis: the total percentage of exercise sessions attended in both groups (conventional vs domiciliary program). And also adherence to the different types of sessions (respiratory, relaxation, aerobic and strength) 1.2. Retention rate: the number of participants who finish the training divided by the number of randomized patients.

    Time frame: First visit; 3 months after discharge (after completing rehabilitation program)

  13. Patient experience

    Patient's experience with both the cardiac rehabilitation program and the use of technology will be assessed using a LIKERT scale (1 Not at all to 5 A lot) asking the following questions: * How do you think a cardiac rehabilitation program can impact your health? * How do you think the use of information technology can impact your health? The results will be analyzed before starting the program and at the end to determine if patient's impression has changed.

    Time frame: First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 30 months is below that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Jun 26, 2025
StartActual
May 26, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038265
Lead sponsor
Institut d'Investigació Biomèdica de Bellvitge
Collaborators
Hospital Universitari de Bellvitge, Fundació La Marató de TV3
Responsible party
Cristina Enjuanes Grau (Coordinator of Community Heart Failure Unit, Cardiology Department. MD, PhD, Institut d'Investigació Biomèdica de Bellvitge) — Principal investigator
First posted
Jun 26, 2025
Start date
May 26, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 26, 2025

Study contacts

Cristina Enjuanes Grau, MD, PhD
Contact
cenjuanes@bellvitgehospital.cat
+34 93 260 7078
Pablo Morales, MD
Contact
pmorales@idibell.cat
+34 93 260 7078
Cristina Enjuanes, MD, PhD
principal investigator · Institut d'Investigació Biomèdica de Bellvitge

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion